FDAnews
www.fdanews.com/articles/101668-lifecycle-pharma-begins-trial-for-lcp-siro

LifeCycle Pharma Begins Trial for LCP-Siro

November 30, 2007
Denmark’s LifeCycle Pharma has started a Phase I trial for LCP-Siro, an immunosuppressant for the prevention of organ rejection after transplantation and for the treatment of certain autoimmune diseases.

 

Data from the LCP-Siro (sirolimus) trial are expected in 2008, LifeCycle said.

Sirolimus is marketed by Wyeth under the brand name Rapamune, which is sold as an oral solution and tablet and also coats the Cypher coronary stent marketed by Johnson & Johnson.